BMY Q3 2017 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q3 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.3B+6.7% YoY

Gross Profit

$3.7B70.2% margin

Operating Income

$1.1B20.3% margin

Net Income

$845M16.1% margin

EPS (Diluted)

$0.51

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$1.7B

Free Cash Flow

$1.5B

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$34.0B

Total Liabilities

$19.1B

Stockholders' Equity

$14.8B

Cash & Equivalents

$4.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.3B	$4.9B	+6.7%
Gross Profit	$3.7B	$3.6B	+2.0%
Operating Income	$1.1B	$1.3B	-20.3%
Net Income	$845M	$1.2B	-29.7%

Revenue Segments

Opdivo

$1.3B24%

Eliquis

$1.2B23%

Orencia

$632M12%

Mature Products And All Other

$539M10%

Sprycel

$509M10%

Yervoy

$323M6%

Baraclude

$264M5%

Sustiva Franchise

$183M3%

Reyataz

$174M3%

Hepatitis C Portfolio

$73M1%

Empliciti

$60M1%